Clinical and Molecular Hepatology

Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”: Seren M. Gedallovich, Paul Y. Kwo; Clin Mol Hepatol 2024;30(4):1050-1052.
Published online July 12, 2024; DOI: https://doi.org/10.3350/cmh.2024.0546

Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”: Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu; Clin Mol Hepatol 2024;30(4):1023-1025.
Published online July 1, 2024; DOI: https://doi.org/10.3350/cmh.2024.0472

Citations

Citations to this article as recorded by

Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)
Chung-Feng Huang, Jeong Heo, Rong-Nan Chien, Yang-Hyun Baek, Jia-Horng Kao, Ju-Hyun Kim, Ting-Tsung Chang, Kwan-Soo Byun, Jyh-Jou Chen, Sook-Hyang Jeong, Tsung-Hui Hu, Young-Seok Kim, Cheng-Yuan Peng, Won-Young Tak, Horng-Yuan Wang, Seung-Kew Yoon, I.-Shy
Infectious Diseases and Therapy.2025; 14(5): 1089. CrossRef
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
Clinical and Molecular Hepatology.2024; 30(4): 807. CrossRef
Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
Seren M. Gedallovich, Paul Y. Kwo
Clinical and Molecular Hepatology.2024; 30(4): 1050. CrossRef

Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”: Seren M. Gedallovich, Paul Y. Kwo; Clin Mol Hepatol 2024;30(4):677-681.
Published online June 11, 2024; DOI: https://doi.org/10.3350/cmh.2024.0418

Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”: Ming-Ying Lu, Ming-Lung Yu; Clin Mol Hepatol 2024;30(2):274-275.
Published online March 5, 2024; DOI: https://doi.org/10.3350/cmh.2024.0152

Citations

Citations to this article as recorded by

Prevalence and Modes of Transmission of Hepatitis C Virus Infection: A Historical Worldwide Review
Tommaso Stroffolini, Giacomo Stroffolini
Viruses.2024; 16(7): 1115. CrossRef
The role of artificial intelligence in the management of liver diseases
Ming‐Ying Lu, Wan‐Long Chuang, Ming‐Lung Yu
The Kaohsiung Journal of Medical Sciences.2024; 40(11): 962. CrossRef